List of Mozobil drug patents
Mozobil is owned by Genzyme.
Mozobil contains Plerixafor.
Mozobil has a total of 2 drug patents out of which 0 drug patents have expired.
Mozobil was authorised for market use on 15 December, 2008.
Mozobil is available in solution;subcutaneous dosage forms.
Mozobil can be used as use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with non-hodgkin's lymphoma & multiple myeloma.
The generics of Mozobil are possible to be released after 22 July, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7897590 | GENZYME | Methods to mobilize progenitor/stem cells |
Jul, 2023
(a month from now) | |
| US6987102 | GENZYME | Methods to mobilize progenitor/stem cells |
Jul, 2023
(a month from now) | |
Drugs and Companies using PLERIXAFOR ingredient
Market Authorisation Date: 15 December, 2008
Treatment: Use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with n...
Dosage: SOLUTION;SUBCUTANEOUS
MOZOBIL family patents
14
United States
4
Norway
4
European Union
3
Japan
2
Luxembourg
2
Korea, Republic of
2
Canada
2
Netherlands
2
Denmark
2
Spain
2
Cyprus
2
Portugal
2
Slovenia
2
China
2
Lithuania
1
Australia
1
Israel
1
New Zealand
1
Austria
1
Russia
1
Poland
1
Hong Kong
1
Mexico
1
Germany
1
Brazil
1
South Africa
1
Hungary
1
Belgium
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic